Distinguished in Paronychia
Check Byoung C. Cho's experience treating your condition:
About Byoung C. Cho

Byoung Cho practices in Sinchon-dong, Republic of Korea. Cho is rated as a Distinguished expert by MediFind in the treatment of Paronychia. They are also highly rated in 15 other conditions, according to our data. Their top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, EGFR Positive Lung Cancer, Tissue Biopsy, and Gamma Knife Radiosurgery.

Their clinical research consists of co-authoring 291 peer reviewed articles and participating in 18 clinical trials in the past 15 years. In particular, they have co-authored 7 articles in the study of Paronychia.

Sinchon-dong, KR
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
Phase II Trial of PF-00299804 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy
An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase II Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
View 11 Less Clinical Trials -

291 Total Publications

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more